Astellas Pharma and Kyntra Bio side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Astellas Pharma | Kyntra Bio |
|---|---|---|
| Phase 1 | Astellas Pharma: 2 of its 20 programs at phase 1
| 00% |
| Phase 2 | Astellas Pharma: 9 of its 20 programs at phase 2
and 4 more — sign in to see them all | Kyntra Bio: 1 of its 2 programs at phase 2 |
| Phase 3 | Astellas Pharma: 4 of its 20 programs at phase 3
| 00% |
| Approved, new studies | Astellas Pharma: 5 of its 20 programs at approved, new studies
| Kyntra Bio: 1 of its 2 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas Pharma9 readouts · 2 phase 3 | · | Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3
| · | · | · | Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion
| · | Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion
|
| Kyntra Bio0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Astellas Pharma
New programs 1
- ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- zolbetuximabphase 1 · Jul 2026 → Dec 2026 (+5 mo) · moved Oct 16 · NCT06396091
Kyntra Bio
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.
| Condition | Astellas Pharma | Kyntra Bio |
|---|---|---|
| Prostatic Neoplasmsboth · compare here | Astellas Pharma in Prostatic Neoplasms: 4 programs
Their studies: Astellas Pharma’s studies of Prostatic Neoplasms in search | Kyntra Bio in Prostatic Neoplasms: 1 program Their studies: Kyntra Bio’s studies of Prostatic Neoplasms in search |
| Renal Insufficiencyboth · compare here | Astellas Pharma in Renal Insufficiency: 2 programs
Their studies: Astellas Pharma’s studies of Renal Insufficiency in search | Kyntra Bio in Renal Insufficiency: 1 program
Their studies: Kyntra Bio’s studies of Renal Insufficiency in search |
| Kidney Failure, Chronicboth · compare here | Astellas Pharma in Kidney Failure, Chronic: 1 program
Their studies: Astellas Pharma’s studies of Kidney Failure, Chronic in search | Kyntra Bio in Kidney Failure, Chronic: 1 program
Their studies: Kyntra Bio’s studies of Kidney Failure, Chronic in search |
| Multiple Myelomaboth · compare here | Astellas Pharma in Multiple Myeloma: 1 program
Their studies: Astellas Pharma’s studies of Multiple Myeloma in search | Kyntra Bio in Multiple Myeloma: 1 program Their studies: Kyntra Bio’s studies of Multiple Myeloma in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.